Leiomyoma pseudocapsule after pre-surgical treatment with gonadotropin-releasing hormone agonists: Relationship between clinical features and immunohistochemical changes

被引:46
作者
De Falco, Marianna [1 ]
Staibano, Stefania [2 ]
Mascolo, Massimo [2 ]
Mignogna, Chiara [2 ]
Improda, Luigi [1 ]
Ciociola, Francesca [1 ]
Carbone, Ilma F. [1 ]
Di Lieto, Andrea [1 ]
机构
[1] Univ Naples Federico 2, Dept Obstet Gynaecol & Urol Sci & Reprod Med, I-80131 Naples, Italy
[2] Univ Naples Federico 2, Dept Biomorphol & Funct Sci, I-80131 Naples, Italy
关键词
Cleavage plan; GnRH-a therapy; Intraoperative blood loss; Leiomyoma pseudocapsule; Myomectomy; UTERINE LEIOMYOMAS; ABDOMINAL MYOMECTOMY; LEUPROLIDE ACETATE; GROWTH-FACTOR; EXPRESSION; PROLIFERATION; APOPTOSIS; BCL-2;
D O I
10.1016/j.ejogrb.2009.02.006
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To evaluate if pre-operative GnRH-a modify uterine leiomyoma pseudocapsule and the possible clinical effects of these changes. Study design: The study was performed at the University Federico II of Naples on 33 premenopausal patients submitted to laparotomic myomectomy after treatment with triptorelin depot. 29 untreated patients formed the control group. The operating time, the intraoperative bleeding and the prompt identification of the cleavage plan between myoma and myometrium were evaluated. The pseudocapsule features and the immunoexpression of PCNA and CD34 in this area were studied. Results: Treated patients showed lower blood loss and not clearly identifiable cleavage plan, but without any significant increase in the operating time. Treated lesions showed less evident border between myoma and myometrium and lower PCNA and CD34 pseudocapsule immunoexpression than untreated ones. Conclusion: We propose the changes of leiomyoma pseudocapsule as partial explanations of the reported clinical and surgical findings after pre-operative GnRH-a. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:44 / 47
页数:4
相关论文
共 16 条
[11]   Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (Leuprolide acetate) [J].
Mizutani, T ;
Sugihara, A ;
Nakamuro, K ;
Terada, N .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (04) :1253-1255
[12]   Histopathologic findings in 107 uterine leiomyomas treated with leuprolide acetate compared with 126 controls [J].
Sreenan, JJ ;
Prayson, RA ;
Biscotti, CV ;
Thornton, MH ;
Easley, KA ;
Hart, WR .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (04) :427-432
[13]   Uterine fibroids [J].
Stewart, EA .
LANCET, 2001, 357 (9252) :293-298
[14]   Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial [J].
Vercellini, P ;
Trespidi, L ;
Zaina, B ;
Vicentini, S ;
Stellato, G ;
Crosignani, PD .
FERTILITY AND STERILITY, 2003, 79 (06) :1390-1395
[15]   Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas [J].
Vu, K ;
Greenspan, DL ;
Wu, TC ;
Zacur, HA ;
Kurman, RJ .
HUMAN PATHOLOGY, 1998, 29 (04) :359-363
[16]   Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy [J].
Walocha, JA ;
Litwin, JA ;
Miodonski, AJ .
HUMAN REPRODUCTION, 2003, 18 (05) :1088-1093